By Condition
What GLP-1s actually treat
These drugs arrived as treatments for diabetes and obesity. The evidence has since reached sleep apnea, cardiovascular risk, PCOS and liver disease — but not equally, which is the point of the grade on each card. Every guide below sets out the condition, says plainly how good the trial evidence is, and names providers that will treat it.
Also explore peptide therapies and the best GLP-1 providers.
Weight & metabolic
Cardiometabolic
Type 2 Diabetes
Evidence AFDA-approved indication (Ozempic, Mounjaro)
Blood sugar runs high because the body stopped responding to insulin. The GLP-1s and the dual GLP-1/GIP drugs pull A1c down and take weight off at once.
Prediabetes
Evidence BOff-label; strong prevention evidence
Readings above normal but short of a diabetes diagnosis. Losing weight at this stage, by any route, is what pushes the progression back or stops it.
Obstructive Sleep Apnea
Evidence AFDA-approved indication (Zepbound)
The airway closes repeatedly through the night, and weight is the dominant driver. Zepbound now carries an FDA approval for the moderate-to-severe form.
Metabolic Syndrome
Evidence BOff-label; improves each component
Five risk factors that arrive together: waist size, blood pressure, sugar, triglycerides and HDL. Weight loss here moves every one the right way.
Cardiovascular Disease Risk
Evidence AFDA-approved risk-reduction indication (Wegovy)
For adults with heart disease alongside obesity or diabetes, these drugs hold an FDA indication for cutting major cardiac events, not just for the weight.